United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. raised its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 31.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,179 shares of the biotechnology company's stock after purchasing an additional 2,211 shares during the period. Cambridge Investment Research Advisors Inc.'s holdings in United Therapeutics were worth $2,830,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. State of Alaska Department of Revenue lifted its position in United Therapeutics by 0.8% during the first quarter. State of Alaska Department of Revenue now owns 16,692 shares of the biotechnology company's stock valued at $5,145,000 after purchasing an additional 135 shares during the period. CWA Asset Management Group LLC increased its stake in shares of United Therapeutics by 51.6% during the first quarter. CWA Asset Management Group LLC now owns 8,224 shares of the biotechnology company's stock worth $2,535,000 after purchasing an additional 2,799 shares in the last quarter. Kingswood Wealth Advisors LLC raised its holdings in shares of United Therapeutics by 16.0% during the first quarter. Kingswood Wealth Advisors LLC now owns 741 shares of the biotechnology company's stock valued at $228,000 after acquiring an additional 102 shares during the last quarter. Cardinal Capital Management boosted its stake in United Therapeutics by 5.7% during the 1st quarter. Cardinal Capital Management now owns 11,699 shares of the biotechnology company's stock worth $3,606,000 after purchasing an additional 631 shares during the last quarter. Finally, Great Lakes Retirement Inc. purchased a new stake in United Therapeutics during the 1st quarter valued at about $1,237,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Raymond Dwek sold 4,000 shares of the business's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the transaction, the director owned 1,750 shares in the company, valued at $497,962.50. The trade was a 69.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the sale, the chief financial officer owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This trade represents a 59.65% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 80,681 shares of company stock worth $23,951,939. 10.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on UTHR shares. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price objective for the company. Morgan Stanley upped their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. Bank of America cut their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Finally, JPMorgan Chase & Co. lowered their target price on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $386.15.

United Therapeutics Stock Down 0.2%

Shares of UTHR traded down $0.65 during mid-day trading on Friday, reaching $294.57. 284,212 shares of the company's stock were exchanged, compared to its average volume of 445,700. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The company has a market cap of $13.29 billion, a price-to-earnings ratio of 11.75, a PEG ratio of 6.45 and a beta of 0.53. The company has a 50-day simple moving average of $301.21 and a two-hundred day simple moving average of $322.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the previous year, the business earned $6.17 earnings per share. The business's revenue for the quarter was up 17.2% on a year-over-year basis. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.